ATMI to sell its LifeSciences Business to Pall

Published: 2-Jan-2014
Finance

Transaction strengthens and broadens Pall offering for biopharmaceutical customers


ATMI is to sell its LifeSciences business to Pall Corporation, a filtration, separation and purification specialist, for US$185m.

The deal includes all assets associated with ATMI's LifeSciences business, including two locations in Belgium plus a shared facility in Minnesota, US.

ATMI, which specialises in single-use bioprocess systems and consumables for the pharma and biopharma industries, expects the transaction to close during the first quarter of this year, subject to regulatory approvals and customary closing conditions.

'We are very happy to have Pall as the new owner of this business, and believe the fit with Pall's capabilities will accelerate its growth and provide great customer support,' said ATMI's Chief Executive, Doug Neugold.

'This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,' added Larry Kingsley, Chairman and CEO of Pall.

  • Companies:
  • Pall Life Sciences
  • ATMI LifeSciences
See more

You may also like

Drug Delivery

Cytiva completes integration with Pall Corporation

Read more
This new Cytiva supports customers in solving major biotechnology challenges, playing a critical role in advancing and accelerating therapeutics

Trending Articles

  1. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  2. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  5. LGC Standards acquires VHG Labs Further strengthening its position in the US

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

Cytiva completes integration with Pall Corporation

This new Cytiva supports customers in solving major biotechnology challenges, playing a critical role in advancing and accelerating therapeutics
Manufacturing

Danaher Corporation to buy Pall Corporation for US$13.8bn

Plans to split into two independent, publicly traded companies
Manufacturing

Pall purchases BioSMB technology from Tarpon Biosystems

Expands downstream continuous processing capabilities
Manufacturing

ATMI and Finesse sign bioprocess reactor agreement

ATMI PadReactor system and Finesse controller technology to be offered as a turnkey system
Manufacturing

ATMI acquires Artelis

Expands portfolio of bioprocess manufacturing and single-use technology products
Packaging

ATMI LifeSciences and Austar complete Beijing facility

Joint venture builds ultra-clean packaging manufacturing for Asian market
Design & Build

ATMI completes expansion of Minnesota facility

Doubles production capacity for single-use bioprocess products
Subscribe now